OBJECTIVE： To provide reference for the sustainable development of pharmaceutical industry in Guizhou province. METHODS： By literature review， personal interview and questionnaire survey， the current situation about the development of pharmaceutical industry in Guizhou province were investigated and analyzed， and the corresponding countermeasures and suggestions were put forward. RESULTS： The literatures were obtained from network literature by Baidu search engine， published data by government portal website of administrative department， documents by CNKI and VIP. Five personal interviews involved the relevant management personnel in Policies and Regulations Department， Medicine and Cosmetics Production Supervision Department， Medical Device Supervision Department of Guizhou Province Food and Drug Administration. A total of 70 questionnaires （drug production enterprises as object） were sent out， and 57 valid questionnaires were collected with the effective recovery rate of 81.4％. In the present， there were a total of 175 pharmaceutical production enterprises （56.5％ in Guiyang city） and 106 medical device manufacturers in Guizhou province. Of 57 pharmaceutical manufacturing enterprises investigated， 87.8％ of them were certified by the 2010 edition of Good Manufacturing Practice （GMP）. The number of varieties of Chinese herbal medicines in Guizhou province ranked second in the whole country； total area of Chinese herbal medicine planting， wild protection and tending ranked third in the whole country in 2015； the industrial output value of Chinese patent medicine accounted for 85.1％ of the total output value of the pharmaceutical industry； but no approved new medicines were class 1 and 2 new medicines； R&D personnel with high education levels took small proportion significantly. The output capacity of chemical medicine industry was far lower than the average national level； the chemical industry output value accounted for only about 10％ of the total output value of the pharmaceutical industry in the province； the rate of success approval was almost zero for new drugs declared by drug manufacturers in recent years. Biological products industry was an emerging industry， currently there were only 3 biological products production enterprises. Of 341 products in medical device industry， there were 146 classⅠproducts， 190 classⅡproducts and 5 classⅢproducts， manifesting as narrow coverage， few production type， relatively backward level. Seven percent of pharmaceutical production enterprise involved in the derivatives industry， and the development of TCM health care industry attracted more and more attention. CONCLUSIONS：  The Chinese and national medicine industry has been the dominant force， the development of chemical medicine， biological products and medical device industry has lagged behind， and medicine derivatives industry needs to promote the integration of TCM and health-and-fitness. The whole industry strategic consciousness is comparatively backward， high-end R&D personnel is lack， and independent innovation ability is weak. It is suggested to done the top design， guide enterprises mergers and restructuring； develop characteristic medicine， support small molecule chemical medicines and biological products enterprises deeply； deepen the understanding of industrial policy， and increase investment in independent innovation； develop new medicine derivatives， and expand the pharmaceutical e-commerce sales channel； broaden the industry chain depth， breadth and width， and excavate medical big data.